All In Biotech

Investigational drug · Phase 2

BMS-986368

Also called: CC-97489

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Agitation, Alzheimer Disease, Multiple Sclerosis Spasticity.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

9

Any phase or sponsor naming "BMS-986368"

First trial start

2025

Jun 5, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BMS-986368", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Agitation
  • Alzheimer Disease
  • Multiple Sclerosis Spasticity

Approved drugs for the same conditions: Alzheimer's disease · Multiple sclerosis · Neurology · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "BMS-986368" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Agitation

  • KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials

    Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder

  • AXS-05dextromethorphan-bupropionPhase 33 trials

    Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation

  • SUVN-502MasupirdinePhase 31 trial

    Suven Life Sciences Limited · Agitation, Alzheimer's Type Dementia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.